Liu X, Yue Z, Yu J, Daguindau E, Kushekhar K, Zhang Q, Ogata Y, Gafken P R, Inamoto Y, Gracon A, Wilkes D S, Hansen J A, Lee S J, Chen J Y, Paczesny S
Department of BioHealth Informatics, Indiana University School of Informatics and Computing, Indianapolis, IN.
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
Am J Transplant. 2016 Aug;16(8):2342-51. doi: 10.1111/ajt.13750. Epub 2016 Mar 14.
Improved diagnostic methods are needed for bronchiolitis obliterans syndrome (BOS), a serious complication after allogeneic hematopoietic cell transplantation (HCT) and lung transplantation. For protein candidate discovery, we compared plasma pools from HCT transplantation recipients with BOS at onset (n = 12), pulmonary infection (n = 16), chronic graft-versus-host disease without pulmonary involvement (n = 15) and no chronic complications after HCT (n = 15). Pools were labeled with different tags (isobaric tags for relative and absolute quantification), and two software tools identified differentially expressed proteins (≥1.5-fold change). Candidate proteins were further selected using a six-step computational biology approach. The diagnostic value of the lead candidate, matrix metalloproteinase 3 (MMP3), was evaluated by enzyme-linked immunosorbent assay in plasma of a verification cohort (n = 112) with and without BOS following HCT (n = 76) or lung transplantation (n = 36). MMP3 plasma concentrations differed significantly between patients with and without BOS (area under the receiver operating characteristic curve 0.77). Consequently, MMP3 represents a potential noninvasive blood test for diagnosis of BOS.
对于闭塞性细支气管炎综合征(BOS)需要改进诊断方法,BOS是异基因造血细胞移植(HCT)和肺移植后的一种严重并发症。为了发现蛋白质候选物,我们比较了HCT移植受者在BOS发病时(n = 12)、肺部感染时(n = 16)、无肺部受累的慢性移植物抗宿主病时(n = 15)以及HCT后无慢性并发症时(n = 15)的血浆池。血浆池用不同的标签(用于相对和绝对定量的等压标签)标记,并且使用两个软件工具鉴定差异表达的蛋白质(≥1.5倍变化)。使用六步计算生物学方法进一步选择候选蛋白质。通过酶联免疫吸附测定法在HCT(n = 76)或肺移植(n = 36)后有或无BOS的验证队列(n = 112)的血浆中评估主要候选物基质金属蛋白酶3(MMP3)的诊断价值。有BOS和无BOS的患者之间MMP3血浆浓度有显著差异(受试者操作特征曲线下面积为0.77)。因此,MMP3代表了一种用于诊断BOS的潜在非侵入性血液检测方法。